𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A Case of Premature Termination in a Treatment for Generalized Anxiety Disorder

✍ Scribed by James F. Boswell; Sandra J. Llera; Michelle G. Newman; Louis G. Castonguay

Book ID
113523078
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
213 KB
Volume
18
Category
Article
ISSN
1077-7229

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Premature termination of treatment in an
Premature termination of treatment in an inpatient eating disorder programme
✍ Philip C. Masson; Christopher M. Perlman; Stuart A. Ross; April L. Gates πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 120 KB

## Abstract This retrospective study was conducted to explore rates, timing and predictors of two forms of premature termination of treatment (PTT) in an inpatient eating disorders programme: patient dropout (DO) and administrative discharge (AD). A chart review was conducted to obtain demographic,

Efficacy of ondansetron in the treatment
Efficacy of ondansetron in the treatment of generalized anxiety disorder
✍ A. M. Freeman III; J. R. Westphal; G. T. Norris; B. A. Roggero; P. B. Webb; K. L πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 42 KB πŸ‘ 2 views

Ondansetron is a highly selective antagonist at the 5-HT 3 subtype of serotonin (5-HT) receptors . The 5-HT 3 receptors are the only receptors whose effects are mediated through the ion channels rather than the G-protein series . Ondansetron has no appreciable affinity for other 5-HT receptor subtyp

Predictors of relapse in a study of dulo
Predictors of relapse in a study of duloxetine treatment for patients with generalized anxiety disorder
✍ J. Alexander Bodkin; Christer Allgulander; Pierre M. Llorca; Melissa E. Spann; D πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 112 KB πŸ‘ 2 views

## Objective Data from a relapse prevention study of duloxetine treatment for adults with generalized anxiety disorder (GAD) were examined to identify predictors of relapse. ## Methods Patients responding to 6 months of open‐label duloxetine treatment were randomized to continuation with duloxeti